This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Sep;7(Suppl 6):S189.

doi: 10.21037/atm.2019.07.36.

Levodopa treatment in Parkinson's disease: earlier or later?

Federico Paolini Paoletti¹, Nicola Tambasco¹, Lucilla Parnetti¹

Affiliations

PMID: 31656768
PMCID: PMC6789370
DOI: 10.21037/atm.2019.07.36

Editorial

Levodopa treatment in Parkinson's disease: earlier or later?

Federico Paolini Paoletti et al. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S189.

doi: 10.21037/atm.2019.07.36.

Authors

Federico Paolini Paoletti¹, Nicola Tambasco¹, Lucilla Parnetti¹

Affiliation

¹ Section of Neurology, University of Perugia, Perugia, Italy.

PMID: 31656768
PMCID: PMC6789370
DOI: 10.21037/atm.2019.07.36

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf MGW, de Haan RJ, de Bie RMA; LEAP Study Group. Verschuur CVM, et al. N Engl J Med. 2019 Jan 24;380(4):315-324. doi: 10.1056/NEJMoa1809983. N Engl J Med. 2019. PMID: 30673543 Clinical Trial.

Similar articles

Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
Fagerlund K, Anderson LC, Gurvich O. Fagerlund K, et al. Am J Nurs. 2013 Jan;113(1):26-35; quiz 36. doi: 10.1097/01.NAJ.0000425744.76107.9f. Am J Nurs. 2013. PMID: 23247677
Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.
Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Virmani T, et al. J Clin Mov Disord. 2016 May 26;3:8. doi: 10.1186/s40734-016-0036-9. eCollection 2016. J Clin Mov Disord. 2016. PMID: 27231577 Free PMC article.
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Montastruc JL, Rascol O, Senard JM, Rascol A. Montastruc JL, et al. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1034-8. doi: 10.1136/jnnp.57.9.1034. J Neurol Neurosurg Psychiatry. 1994. PMID: 8089666 Free PMC article. Clinical Trial.
Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ, Spencer CM. Matheson AJ, et al. Drugs. 2000 Jul;60(1):115-37. doi: 10.2165/00003495-200060010-00007. Drugs. 2000. PMID: 10929932 Review.
Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
Fiala KH, Whetteckey J, Manyam BV. Fiala KH, et al. Parkinsonism Relat Disord. 2003 Aug;9(6):321-7. doi: 10.1016/s1353-8020(03)00040-3. Parkinsonism Relat Disord. 2003. PMID: 12853231 Review.

See all similar articles

Cited by

A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.
Muddapu VR, Vijayakumar K, Ramakrishnan K, Chakravarthy VS. Muddapu VR, et al. Front Neurosci. 2022 Apr 19;16:797127. doi: 10.3389/fnins.2022.797127. eCollection 2022. Front Neurosci. 2022. PMID: 35516806 Free PMC article.
Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.
Tryphena KP, Anuradha U, Kumar R, Rajan S, Srivastava S, Singh SB, Khatri DK. Tryphena KP, et al. J Alzheimers Dis. 2023;94(s1):S187-S202. doi: 10.3233/JAD-220449. J Alzheimers Dis. 2023. PMID: 35848027 Free PMC article. Review.
A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease.
Muddapu VR, Chakravarthy VS. Muddapu VR, et al. Front Neuroinform. 2020 Sep 30;14:34. doi: 10.3389/fninf.2020.00034. eCollection 2020. Front Neuroinform. 2020. PMID: 33101001 Free PMC article.
Using a deep recurrent neural network with EEG signal to detect Parkinson's disease.
Xu S, Wang Z, Sun J, Zhang Z, Wu Z, Yang T, Xue G, Cheng C. Xu S, et al. Ann Transl Med. 2020 Jul;8(14):874. doi: 10.21037/atm-20-5100. Ann Transl Med. 2020. Retraction in: Ann Transl Med. 2021 Sep;9(17):1396. doi: 10.21037/atm-2021-25. PMID: 32793718 Free PMC article. Retracted.

References

1. Olanow CW, Stocchi F. Levodopa: A new look at an old friend. Mov Disord 2018;33:859-66. 10.1002/mds.27216 - DOI - PubMed
1. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-76. 10.1056/NEJMct0800326 - DOI - PubMed
1. Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-71. 10.1002/mds.25364 - DOI - PubMed
1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58. 10.1002/mds.1090 - DOI - PubMed
1. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9. 10.1002/mds.20324 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources